Published in Heart on March 01, 2006
Twelve-month outcomes in patients with diabetes implanted with a zotarolimus-eluting stent: results from the E-Five Registry. Heart (2010) 0.90
Revascularization for coronary artery disease in diabetes mellitus: angioplasty, stents and coronary artery bypass grafting. Rev Endocr Metab Disord (2010) 0.90
Nanoporous CREG-eluting stent attenuates in-stent neointimal formation in porcine coronary arteries. PLoS One (2013) 0.81
Comparison of 12-month clinical outcomes in diabetic and nondiabetic patients with chronic total occlusion lesions: a multicenter study. Coron Artery Dis (2015) 0.80
Effect of a novel peptide, WKYMVm- and sirolimus-coated stent on re-endothelialization and anti-restenosis. J Mater Sci Mater Med (2015) 0.80
Favorable Outcomes after Implantation of Biodegradable Polymer Coated Sirolimus-Eluting Stents in Diabetic Population: Results from INDOLIMUS-G Diabetic Registry. Int J Vasc Med (2015) 0.78
Long-term type 1 diabetes enhances in-stent restenosis after aortic stenting in diabetes-prone BB rats. J Biomed Biotechnol (2011) 0.75
Comparison of clinical outcomes after drug-eluting stent implantation in diabetic versus nondiabetic patients in China: A retrospective study. Medicine (Baltimore) (2017) 0.75
Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA (2005) 9.81
Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA (2002) 8.81
Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med (2005) 3.75
A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet (2004) 3.52
Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol (2005) 3.17
Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation (2004) 3.12
Evidence for use of coronary stents. A hierarchical bayesian meta-analysis. Ann Intern Med (2003) 2.79
Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol (2005) 2.50
Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol (2004) 2.14
A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: one- to eight-year outcomes. J Am Coll Cardiol (2003) 2.10
Molecular basis of restenosis and drug-eluting stents. Circulation (2005) 2.08
Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol (2005) 2.00
Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation (2004) 1.83
Meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting. Diabetes Care (2004) 1.70
Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation (2005) 1.67
Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol (2005) 1.59
Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA (2005) 1.57
Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus. Circulation (2005) 1.55
Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation (2005) 1.50
Diabetes and coronary revascularization. JAMA (2005) 1.45
Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation (2005) 1.38
Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol (2000) 1.33
Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial. J Am Coll Cardiol (2005) 1.19
Relationship of late loss in lumen diameter to coronary restenosis in sirolimus-eluting stents. Circulation (2005) 1.04
Drug-eluting stents: meta-analysis in diabetic patients. Eur Heart J (2004) 0.99
Comparison of short- (one month) and long- (twelve months) term outcomes of sirolimus- versus paclitaxel-eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T-SEARCH registries). Am J Cardiol (2005) 0.90
Comparison of late luminal loss response pattern after sirolimus-eluting stent implantation or conventional stenting. Circulation (2004) 0.82